Lipid alterations play a role in the integration of PD-1/PD-L1 inhibitors and anlotinib for the treatment of advanced non-small-cell lung cancer

• Published in: Lipids in health and disease 2024-01, Vol.23 (1), p.16-16, Article 16
• Main Authors: Liu, Li, Zhang, Shuo, Yang, Hai-Yan, Zhou, Chun-Hua, Xiong, Yi, Yang, Nong, Tian, Ye
• Format: Article
• Language: English
• Subjects: Advanced NSCLC; Anlotinib alongside PD-1/PD-L1 inhibitors; Antibodies; Apoptosis; Cancer therapies; Carcinoma, Non-Small-Cell Lung - drug therapy; Carcinoma, Non-Small-Cell Lung - genetics; Chemotherapy; Chemotherapy, Combination; Development and progression; Disease; Drug therapy; Genetic testing; Health aspects; Humans; Immune Checkpoint Inhibitors - pharmacology; Immune Checkpoint Inhibitors - therapeutic use; Immunotherapy; Indoles; Kinases; Lipid composition; Lipid metabolism; Lipids; Lipids - therapeutic use; Lung cancer; Lung cancer, Non-small cell; Lung Neoplasms - drug therapy; Lung Neoplasms - genetics; Metabolism; Methods; Monoclonal antibodies; Mutation; Non-small cell lung carcinoma; Oncology; Patients; PD-1 protein; PD-L1 protein; Performance evaluation; Phosphatidylglycerol; Phosphoinositides; Physiological aspects; Prognosis; Programmed Cell Death 1 Receptor - genetics; Programmed Cell Death 1 Receptor - metabolism; Programmed Cell Death 1 Receptor - therapeutic use; Quinolines; Small cell lung carcinoma; Therapeutic effect
• ISSN: 1476-511X; 1476-511X
• DOI: 10.1186/s12944-023-01960-7

Studies have shown that integrating anlotinib with programmed death 1 (PD-1)/programmed death-ligand 1 (PD-L1) inhibitors enhances survival rates among progressive non-small-cell lung cancer (NSCLC) patients lacking driver mutations. However, not all individuals experience clinical benefits from this therapy. As a result, it is critical to investigate the factors that contribute to the inconsistent response of patients. Recent investigations have emphasized the importance of lipid metabolic reprogramming in the development and progression of NSCLC. The objective of this investigation was to examine the correlation between lipid variations and observed treatment outcomes in advanced NSCLC patients who were administered PD-1/PD-L1 inhibitors alongside anlotinib. A cohort composed of 30 individuals diagnosed with advanced NSCLC without any driver mutations was divided into three distinct groups based on the clinical response to the combination treatment, namely, a group exhibiting partial responses, a group manifesting progressive disease, and a group demonstrating stable disease. The lipid composition of patients in these groups was assessed both before and after treatment. Significant differences in lipid composition among the three groups were observed. Further analysis revealed 19 differential lipids, including 2 phosphatidylglycerols and 17 phosphoinositides. This preliminary study aimed to explore the specific impact of anlotinib in combination with PD-1/PD-L1 inhibitors on lipid metabolism in patients with advanced NSCLC. By investigating the effects of using both anlotinib and PD-1/PD-L1 inhibitors, this study enhances our understanding of lipid metabolism in lung cancer treatment. The findings from this research provide valuable insights into potential therapeutic approaches and the identification of new therapeutic biomarkers.